research
Engineered Bacteria Carry an Immune Signal Into Tumors
A modified Bifidobacterium delivered an altered IL-2 payload to oxygen-poor pancreatic tumors in animal models.
Summary
A modified Bifidobacterium delivered an altered IL-2 payload to oxygen-poor pancreatic tumors in animal models.
University of Chicago researchers engineered Bifidobacterium longum to accumulate in hypoxic tumors and release a modified interleukin-2 payload. In mouse models of pancreatic cancer, the system activated tumor-fighting CD8 T cells and improved responses when combined with chemotherapy, radiation, or anti-PD-L1 treatment. The work has not been tested in people, and safety and control of a living therapy remain open questions.
Why it matters
A modified Bifidobacterium delivered an altered IL-2 payload to oxygen-poor pancreatic tumors in animal models.
Limits and context
- The work has not been tested in people, and safety and control of a living therapy remain open questions.
Key claims
A modified Bifidobacterium delivered an altered IL-2 payload to oxygen-poor pancreatic tumors in animal models.
Qualification: The work has not been tested in people, and safety and control of a living therapy remain open questions.
Evidence: source-2026-07-25-004
Sources
- University of Chicago via EurekAlert: BifidoSumIL-2University of Chicago via EurekAlert · official announcement
Corrections
No corrections have been recorded for this story.